158 related articles for article (PubMed ID: 21825289)
1. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.
Akers KS; Cota JM; Frei CR; Chung KK; Mende K; Murray CK
Antimicrob Agents Chemother; 2011 Oct; 55(10):4639-42. PubMed ID: 21825289
[TBL] [Abstract][Full Text] [Related]
2. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System.
Por ED; Akers KS; Chung KK; Livezey JR; Selig DJ
J Clin Pharmacol; 2021 Sep; 61(9):1182-1194. PubMed ID: 33811332
[TBL] [Abstract][Full Text] [Related]
5. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
[TBL] [Abstract][Full Text] [Related]
6. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.
Akers KS; Cota JM; Chung KK; Renz EM; Mende K; Murray CK
J Burn Care Res; 2012; 33(6):e254-62. PubMed ID: 22878490
[TBL] [Abstract][Full Text] [Related]
7. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration.
Akers KS; Rowan MP; Niece KL; Stewart IJ; Mende K; Cota JM; Murray CK; Chung KK
Antimicrob Agents Chemother; 2015 Jan; 59(1):46-52. PubMed ID: 25313211
[TBL] [Abstract][Full Text] [Related]
8. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
[TBL] [Abstract][Full Text] [Related]
9. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.
Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
[TBL] [Abstract][Full Text] [Related]
13. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration.
Armendariz E; Chelluri L; Ptachcinski R
Crit Care Med; 1990 Jun; 18(6):675-6. PubMed ID: 2344762
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
Zheng J; Sun Z; Sun L; Zhang X; Hou G; Han Q; Li X; Liu G; Gao Y; Ye M; Wang H; Yu K
J Infect Dis; 2020 Mar; 221(Suppl 2):S279-S287. PubMed ID: 32176792
[TBL] [Abstract][Full Text] [Related]
16. Phenytoin removal by continuous venovenous hemofiltration.
Oltrogge KM; Peppard WJ; Saleh M; Regner KR; Herrmann DJ
Ann Pharmacother; 2013 Sep; 47(9):1218-22. PubMed ID: 24259740
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
[TBL] [Abstract][Full Text] [Related]
18. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study.
Chung KK; Lundy JB; Matson JR; Renz EM; White CE; King BT; Barillo DJ; Jones JA; Cancio LC; Blackbourne LH; Wolf SE
Crit Care; 2009; 13(3):R62. PubMed ID: 19409089
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
[TBL] [Abstract][Full Text] [Related]
20. Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
Krueger CK; Bruno JJ; Tverdek FP; Hernandez M; Abudayyeh A
Ann Pharmacother; 2023 Jun; 57(6):629-636. PubMed ID: 36062536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
